MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
16.51
+0.28
+1.73%
Pre Market: 16.82 +0.31 +1.86% 04:27 09/25 EDT
OPEN
16.09
PREV CLOSE
16.23
HIGH
16.65
LOW
15.88
VOLUME
1
TURNOVER
0
52 WEEK HIGH
27.31
52 WEEK LOW
11.92
MARKET CAP
3.08B
P/E (TTM)
-4.9614
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Is Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations?
Simply Wall St · 3d ago
Weekly Report: what happened at DYN last week (0914-0918)?
Weekly Report · 3d ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 09/17 15:05
What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders
Simply Wall St · 09/17 05:25
Weekly Report: what happened at DYN last week (0907-0911)?
Weekly Report · 09/14 10:23
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 09/11 18:10
Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)
TipRanks · 09/10 18:40
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Webull offers Dyne Therapeutics, Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.